CN115487267B - A Chinese medicinal extract with sleep improving effect, and its preparation method - Google Patents
A Chinese medicinal extract with sleep improving effect, and its preparation method Download PDFInfo
- Publication number
- CN115487267B CN115487267B CN202211184880.3A CN202211184880A CN115487267B CN 115487267 B CN115487267 B CN 115487267B CN 202211184880 A CN202211184880 A CN 202211184880A CN 115487267 B CN115487267 B CN 115487267B
- Authority
- CN
- China
- Prior art keywords
- sleep
- extract
- traditional chinese
- chinese medicine
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000000694 effects Effects 0.000 title abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 35
- 240000004638 Dendrobium nobile Species 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 abstract description 10
- BJQWYEJQWHSSCJ-UHFFFAOYSA-N heptacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC BJQWYEJQWHSSCJ-UHFFFAOYSA-N 0.000 abstract description 10
- 230000004617 sleep duration Effects 0.000 abstract description 8
- 230000004620 sleep latency Effects 0.000 abstract description 7
- -1 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester Chemical class 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- HFDLDPJYCIEXJP-UHFFFAOYSA-N 6-methoxyquinoline Chemical compound N1=CC=CC2=CC(OC)=CC=C21 HFDLDPJYCIEXJP-UHFFFAOYSA-N 0.000 abstract description 5
- 208000000044 Amnesia Diseases 0.000 abstract description 5
- 208000031091 Amnestic disease Diseases 0.000 abstract description 5
- 230000006986 amnesia Effects 0.000 abstract description 5
- 208000002173 dizziness Diseases 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- KJHCCMUTGMDMCT-UHFFFAOYSA-N 1-ethenyl-3-hydroxypyrrolidin-2-one Chemical compound OC1CCN(C=C)C1=O KJHCCMUTGMDMCT-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 235000010331 calcium propionate Nutrition 0.000 description 2
- 239000004330 calcium propionate Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 2
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 2
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 229940073505 ethyl vanillin Drugs 0.000 description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- 235000017454 sodium diacetate Nutrition 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 229940125724 sleeping drug Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The application discloses a traditional Chinese medicine extract with a sleep improving effect in the technical field of medicines, which comprises the following components in percentage by mass: 6-methoxyquinoline oxynitride, 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester and n-heptacosane, wherein the mass percentages of the substances are not lower than 5.0 percent. The traditional Chinese medicine extract in the scheme can obviously shorten the sleep latency period and obviously prolong the sleep duration time, so that the traditional Chinese medicine extract has an exact function of promoting sleep, and the problems that common sleep-promoting medicines have larger toxic and side effects of livers and kidneys, are easy to generate bad symptoms such as dizziness and amnesia, and are easy to generate dependence on the medicines can be well solved.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine extract with a sleep improving effect and a preparation method thereof.
Background
Along with the development of science and technology and the progress of society, people pay more and more attention to health, and sleep difficulty, sleep depth or too short frequency, early waking, sleep duration deficiency or sleep quality poor and other insomnia situations caused by various reasons occur, so that the health care pillow has become a common disease puzzling the public. Sleep is extremely precise symbiotic activity, and if abnormal brain waves occur at a certain stage in the sleep process or even in the whole sleep process, insomnia is possibly caused, and is always accompanied by mental disorder, and insomnia is a pre-stage obstacle which causes drug dependence, alcohol dependence, gunpowder poisoning and the like of sleeping drugs and the like, so that the method has social significance on how to overcome the insomnia and prevent the occurrence of the problems.
At present, aiming at the treatment of insomnia symptoms, the traditional Chinese medicines and the western medicines have different methods, wherein the western medicines often use large-dose sleep-promoting medicines to achieve the effect of promoting sleep by generating different degrees of inhibition effects on various links of various parts of a central nervous system, and the existing researches show that the sleeping-promoting medicines or medicines containing melatonin have the following defects: 1. has larger toxic and side effects of liver and kidney; 2. the aim of thoroughly and radically treating insomnia is difficult to achieve; 3. bad symptoms such as dizziness, amnesia and the like are easy to occur; 4. long-term administration may be dependent on the drug; and 5, requiring doctor instruction to take the medicine, not all sleep disorder persons can take the medicine. Therefore, the search for the development of safe and effective sleep-promoting medicaments has very important meaning and value.
The traditional Chinese medicine has very good curative effect in improving sleep, for example, chinese medicinal materials such as the wild jujube seed and the like are recorded by the traditional Chinese medicine books for the past, and have exact sleep improving effect.
Dendrobium nobile (Dendrobium nobile Lindl.) is also called herba Hedyotidis Diffusae, radix Oenotherae Erythrosepalae, etc., which is a plant of Dendrobium genus of Orchidaceae family, is a traditional and famous and precious medicinal plant in our country, and has been listed as the top grade in Shennong Ben Cao Jing as one of "Jiudaxiancao". The medicinal part is fresh or dry stem, and has effects of strengthening yin, replenishing vital essence, thickening intestine and stomach, and reducing weight for prolonging life. Modern pharmacological researches show that the main active ingredients of dendrobium nobile lindl are alkaloids and polysaccharide compounds, and have multiple effects of resisting tumor, resisting oxidation and aging, enhancing immunity, regulating gastrointestinal movement, reducing blood sugar and blood fat and the like. The inventor sends out the dendrobium nobile flower CO in the study in the early stage 2 The supercritical extract has good sleep improving effect.
Based on the reasons, the invention provides the dendrobium nobile flower CO 2 The supercritical extract solves the problems that the current common sleep-promoting medicine has larger toxic and side effects of liver and kidney, is easy to generate adverse symptoms such as dizziness, amnesia and the like, and is easy to generate dependence on the medicine.
Disclosure of Invention
The invention aims to provide a dendrobium nobile flower CO 2 The supercritical extract solves the problems that the current common sleep-promoting medicine has larger toxic and side effects of liver and kidney, is easy to generate adverse symptoms such as dizziness, amnesia and the like, and is easy to generate dependence on the medicine.
In order to solve the technical problems, the invention provides the following technical scheme: a Chinese medicinal extract with sleep improving effect comprises the following components in percentage by mass: 6-methoxyquinoline oxynitride, 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester and n-heptacosane, wherein the mass percentages of the substances are not lower than 5.0 percent.
A preparation method of a traditional Chinese medicine extract with sleep improving effect comprises the following steps:
s1: taking dendrobium nobile flower and loading CO 2 Extracting in an extraction kettle of a supercritical extraction instrument, wherein the pressure of the extraction kettle is set to be 27.5MPa, the temperature is 46-47 ℃, and the extraction is carried out for 180min;
s2: from CO after extraction is completed 2 Separating out the dendrobium nobile flower CO from the separating kettle of the supercritical extractor 2 Supercritical extract, partial pressure I during separation: 6.9MPa; i, temperature: 38-39 ℃; II partial pressure: 5.9MPa; II, temperature: 44-45 ℃.
Further, the traditional Chinese medicine extract is used for preparing a medicinal preparation, wherein the medicinal preparation comprises capsules, tablets, granules, oral liquid, paste, fog, dripping pills, mixture, slurry, powder or teabags.
Further, the pharmaceutical preparation also comprises pharmaceutical excipients.
Further, the pharmaceutical excipients comprise one or more of diluents, disintegrants, binders, preservatives, antioxidants, flavoring agents, suspending agents and emulsifiers;
the diluent is one or more of mannitol, sucrose, lactose, sorbitol, xylitol, polyethylene glycol, propylene glycol, vegetable oil and mineral oil;
the disintegrating agent is one or more of croscarmellose sodium, colloidal silicon dioxide and citric acid;
the adhesive is one or more of starch slurry, ethanol, water and povidone alcohol solution;
the antiseptic is one or more of ethyl p-hydroxybenzoate, propyl hydroxybenzoate, sorbic acid, potassium sorbate, calcium propionate, sodium dehydroacetate, sodium diacetate and sodium lactate;
the antioxidant is one or more of ethylenediamine tetraacetic acid, disodium ethylenediamine tetraacetate, dibutyl hydroxy toluene, glycine, inositol, ascorbic acid, sodium ascorbate, lecithin, malic acid, hydroquinone, citric acid, succinic acid and sodium metabisulfite;
the flavoring agent is one or more of aspartame, sucrose, xylitol, stevioside, sodium cyclamate, sorbitol, cocoa, pure vanilla, vanillin, ethyl vanillin, chocolate, malt, and herba Menthae;
the suspending agent is one or more of xanthan gum, polyvinylpyrrolidone, sodium alginate, aluminum stearate and hydrogenated vegetable oil;
the emulsifier is one or more of alkyl sulfate, soap, dodecylbenzene sulfonate, lactate, sulfosuccinate, monoglyceride sulfonate, phosphate, siloxane, and taurine salt.
Further, the pharmaceutical preparation is added into a medicament, food or health care product for preventing or treating sleep disorder or promoting sleep after being prepared.
The invention has the beneficial effects that: the traditional Chinese medicine extract in the scheme can obviously shorten the sleep latency period and obviously prolong the sleep duration time, so that the traditional Chinese medicine extract has an exact function of promoting sleep, and the problems that common sleep-promoting medicines have larger toxic and side effects of livers and kidneys, are easy to generate bad symptoms such as dizziness and amnesia, and are easy to generate dependence on the medicines can be well solved.
Drawings
FIG. 1 is a graph showing the effect of the extract of Chinese medicinal materials on sleep latency in an embodiment of the present invention;
FIG. 2 is a graph showing the effect of the extract of Chinese medicinal materials on sleep duration according to the embodiment of the present invention.
Detailed Description
The diluent is one or more of mannitol, sucrose, lactose, sorbitol, xylitol, polyethylene glycol, propylene glycol, vegetable oil and mineral oil;
the disintegrating agent is one or a mixture of several of croscarmellose sodium, colloidal silicon dioxide and citric acid;
the adhesive is one or a mixture of more of starch slurry, ethanol, water and povidone alcohol solution;
the preservative is one or more of ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid, potassium sorbate, calcium propionate, sodium dehydroacetate, sodium diacetate and sodium lactate;
the antioxidant is one or more of ethylenediamine tetraacetic acid, disodium ethylenediamine tetraacetate, dibutyl hydroxy toluene, glycine, inositol, ascorbic acid, sodium ascorbate, lecithin, malic acid, hydroquinone, citric acid, succinic acid and sodium metabisulfite;
the flavoring agent is one or more of aspartame, sucrose, xylitol, stevioside, sodium cyclamate, sorbitol, cocoa, pure vanilla, vanillin, ethyl vanillin, chocolate, malt, and herba Menthae;
the suspending agent is one or more of xanthan gum, polyvinylpyrrolidone, sodium alginate, aluminum stearate and hydrogenated vegetable oil;
the emulsifier is one or more of alkyl sulfate, soap, dodecyl benzene sulfonate, lactate, sulfosuccinate, monoglyceride sulfonate, phosphate, siloxane, and taurine.
Example 1
A Chinese medicinal extract with sleep improving effect comprises the following components in percentage by mass: 6-methoxyquinoline oxynitride, 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester and n-heptacosane, wherein the mass percentages of the substances are not lower than 5.0 percent.
Adding medicinal adjuvants into the Chinese medicinal extract, wherein the medicinal adjuvants are mixture of diluent, disintegrating agent and binder.
And preparing the traditional Chinese medicine extract added with the medicinal auxiliary materials into one of capsules, tablets, granules, oral liquid, ointment, mist, dripping pills, mixture, slurry, powder or teabags.
Example 2
A Chinese medicinal extract with sleep improving effect comprises the following components in percentage by mass: 6-methoxyquinoline oxynitride, 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester and n-heptacosane, wherein the mass percentages of the substances are not lower than 5.0 percent.
Adding medicinal adjuvants into the Chinese medicinal extract, wherein the medicinal adjuvants are mixture of antiseptic, antioxidant and flavoring agent.
And preparing the traditional Chinese medicine extract added with the medicinal auxiliary materials into one of capsules, tablets, granules, oral liquid, ointment, mist, dripping pills, mixture, slurry, powder or teabags.
Example 3
A Chinese medicinal extract with sleep improving effect comprises the following components in percentage by mass: 6-methoxyquinoline oxynitride, 2-fluoro-6-trifluoromethyl-3, 5-difluorophenyl ester and n-heptacosane, wherein the mass percentages of the substances are not lower than 5.0 percent.
Adding medicinal adjuvants into the Chinese medicinal extract, wherein the medicinal adjuvants are mixture of diluent, suspending agent and emulsifying agent.
And preparing the traditional Chinese medicine extract added with the medicinal auxiliary materials into one of capsules, tablets, granules, oral liquid, ointment, mist, dripping pills, mixture, slurry, powder or teabags.
The preparation method of the traditional Chinese medicine extract in the embodiments 1-3 comprises the following steps:
s1: taking dendrobium nobile flower and loading CO 2 Extracting in an extraction kettle of a supercritical extraction instrument, wherein the pressure of the extraction kettle is set to be 27.5MPa, the temperature is 46 ℃ or 47 ℃ during extraction, and the extraction is carried out for 180min;
s2: from CO after extraction is completed 2 Separating out the dendrobium nobile flower CO from the separating kettle of the supercritical extractor 2 Supercritical extract, partial pressure I during separation: 6.9MPa; i, temperature: 38 ℃ or 39 ℃; II partial pressure: 5.9MPa; II, temperature: 44-45 ℃.
Sleep improvement effect observation experiment of dendrobium nobile flower CO2 supercritical extract
1) Experimental method
ICR mice (20-24 g) were purchased from St Bei Fu (Beijing) Biotechnology Co., ltd. [ license number: SCXK (Beijing) 2019-0010, and feeding the rice in an environment with alternating illumination and darkness for 12 hours at room temperature of 20+/-2 ℃ and relative humidity of 50% -70%, and drinking water and diet freely during the period.
The mice were randomly divided into a blank control group, a positive control group, an extract high dose group, an extract medium dose group, and an extract low dose group, 5 groups of 10 animals each. Filling the blank control group with distilled water with corresponding volume; positive control group was intragastric diazepam (1.5 mg/kg); the mice of each group were asleep by intraperitoneal injection of sodium pentobarbital at a dose of 40mg/kg after 1h of gastric administration, which was a high dose of extract (100 mg/kg), medium dose of extract (50 mg/kg) and low dose of extract (25 mg/kg). The latency to sleep and duration of sleep were recorded for each group of mice during the experiment.
2) Experimental results
The experimental results are shown in fig. 1 and fig. 2, the experimental data are expressed as mean ± standard deviation (x±s), fig. 1 is the experimental result of the sleep latency period of the mice, and fig. 2 is the experimental result of the sleep duration period of the mice. Wherein, compared to the blank group, x represents P <0.05; * Represents P <0.01.
The results show that: the positive control group had significantly shortened sleep latency, significantly increased sleep duration, and had very significant differences (P < 0.01) compared to the placebo group. In terms of sleep latency, the sleep latency of the high-dose group and the medium-dose group of dendrobium nobile flower extract is significantly shortened (P < 0.05) compared with that of a blank control group; in terms of sleep duration, the sleep duration of the high and medium dose groups of dendrobium nobile flower extract was significantly prolonged (P < 0.05) compared to the blank control group. The experimental results show that the dendrobium nobile flower CO2 supercritical extract has an exact function of improving sleep.
Claims (1)
1. The application of the traditional Chinese medicine extract in preparing the medicine with the function of improving sleep is characterized in that the preparation method of the traditional Chinese medicine extract comprises the following steps:
s1: putting dendrobium nobile flowers into an extraction kettle of a CO2 supercritical extractor for extraction, wherein the pressure of the extraction kettle is set to be 27.5MPa, the temperature is 46-47 ℃, and the extraction is carried out for 180min;
s2: separating the CO2 supercritical extract of the dendrobium nobile flower from a separating kettle of a CO2 supercritical extractor after the extraction is finished, and separating the CO2 supercritical extract by the partial pressure I: 6.9MPa; i, temperature: 38-39 ℃; II partial pressure: 5.9MPa; II, temperature: 44-45 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211184880.3A CN115487267B (en) | 2022-09-27 | 2022-09-27 | A Chinese medicinal extract with sleep improving effect, and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211184880.3A CN115487267B (en) | 2022-09-27 | 2022-09-27 | A Chinese medicinal extract with sleep improving effect, and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115487267A CN115487267A (en) | 2022-12-20 |
CN115487267B true CN115487267B (en) | 2024-04-09 |
Family
ID=84471932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211184880.3A Active CN115487267B (en) | 2022-09-27 | 2022-09-27 | A Chinese medicinal extract with sleep improving effect, and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115487267B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107029115A (en) * | 2017-03-30 | 2017-08-11 | 温岭市锦华铁皮石斛有限公司 | A kind of natural hair-loss preventing and hair-restoring stem of noble dendrobium caul-fat |
CN111643603A (en) * | 2020-06-02 | 2020-09-11 | 西南医科大学附属中医医院 | Dendrobium nobile extract for improving cognitive decline caused by stress and preparation method and application thereof |
CN113069507A (en) * | 2021-03-30 | 2021-07-06 | 龚德钦 | Dendrobium stem capsule and preparation method thereof |
-
2022
- 2022-09-27 CN CN202211184880.3A patent/CN115487267B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107029115A (en) * | 2017-03-30 | 2017-08-11 | 温岭市锦华铁皮石斛有限公司 | A kind of natural hair-loss preventing and hair-restoring stem of noble dendrobium caul-fat |
CN111643603A (en) * | 2020-06-02 | 2020-09-11 | 西南医科大学附属中医医院 | Dendrobium nobile extract for improving cognitive decline caused by stress and preparation method and application thereof |
CN113069507A (en) * | 2021-03-30 | 2021-07-06 | 龚德钦 | Dendrobium stem capsule and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
The Cognitive-Enhancing Effects of Dendrobium nobile Lindl Extract in Sleep Deprivation-Induced Amnesic Mice;Ning Jiang等;Frontiers in Psychiatry;20220119;第12卷;Article 596017 * |
金钗石斛对慢性疲劳综合征大鼠肝脏及行为学的保护作用;陈莹;中国优秀硕士学位论文全文数据库 医药卫生科技(第8期);第6页第1段,第10页1.5实验方法部分,摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN115487267A (en) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2395293C2 (en) | Pharmaceutical composition for treatment of depression and method of obtaining it | |
US7887855B2 (en) | Formulations containing Cynara scolymus and Phaseolus vulgaris extracts which are useful in the treatment of obesity | |
JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
WO2018117659A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
WO2008011173A2 (en) | Improvement of arginase levels/activity | |
WO2009070915A1 (en) | Pharmaceutical compositions for treating depression and anxiety | |
JP2006083151A (en) | Composition for preventing and ameliorating osteoporosis | |
CN113543794B (en) | Composition for preventing or treating respiratory diseases caused by fine dust comprising extract of Agastache rugosa and Glycyrrhiza glabra | |
CN115487267B (en) | A Chinese medicinal extract with sleep improving effect, and its preparation method | |
JP2001518481A (en) | Serotonin-containing preparations for oral administration and methods of use | |
US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
CN109430854B (en) | Health product and preparation method thereof | |
KR101735061B1 (en) | Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity | |
US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
JP2019006699A (en) | Mild cognitive impairment improving composition | |
CN115364172B (en) | Pharmaceutical composition for promoting sleep | |
KR101521341B1 (en) | Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract | |
WO2009103164A1 (en) | Anti-obesity compositions comprising orlistat and various natural products | |
CN107126450B (en) | A Chinese medicinal preparation containing extract and effective substance, and its preparation method and application | |
KR0137897B1 (en) | Health food containing leaf of eucommia ulmoides oliver | |
JP2009269896A (en) | Raw material of anti-diabetic food or medicine, and anti-diabetic food or medicine | |
JP2618286B2 (en) | Hypotensive yeast preparation and its production method | |
JP6634495B1 (en) | Pharmaceutical composition for promoting estradiol production and food composition | |
CN111356470A (en) | Fraction of analgesic effect of piper nigrum leaf extract | |
WO2021112263A1 (en) | Adiponectin production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |